<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975676</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000650841</org_study_id>
    <secondary_id>IBCSG 24-02-SOFT-EST</secondary_id>
    <secondary_id>SOLTI 0801</secondary_id>
    <secondary_id>BIG 2-02</secondary_id>
    <nct_id>NCT00975676</nct_id>
  </id_info>
  <brief_title>Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02</brief_title>
  <acronym>SOFT-EST</acronym>
  <official_title>A Substudy of the IBCSG 24-02/ SOFT Trial to Investigate Estrogen Suppression for Patients Participating in Arms B and C of the IBCSG 24-02/ SOFT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may
      help doctors learn how well triptorelin given together with tamoxifen citrate or exemestane
      works in lowering estrogen levels.

      PURPOSE: This clinical trial is studying estrogen levels in premenopausal women who have
      undergone surgery for breast cancer and are receiving triptorelin and tamoxifen citrate or
      exemestane on clinical trial IBCSG-2402.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Describe estrogen levels (estradiol [E2], estrone [E1], and estrone sulphate [E1S]) at
           different time points during the first 4 years of treatment with triptorelin in
           combination with either tamoxifen citrate or exemestane on clinical trial IBCSG-2402 in
           premenopausal women with resected breast cancer.

        -  Assess whether there is a suboptimally estrogen-suppressed subgroup of patients who
           receive exemestane.

      Secondary

        -  Compare estrogen levels (E2, E1, E1S) at different time points during treatment with
           triptorelin in combination with either tamoxifen citrate or exemestane.

        -  Examine potential predictive factors of ineffective estrogen suppression (e.g., age,
           chemotherapy [yes/no], type of chemotherapy received, smoking history, BMI, and evidence
           of menses at study entry).

        -  Investigate the predictive value of optimal estrogen suppression during the first 6 and
           12 months of treatment with regard to long-term estrogen suppression (4-year period).

        -  Compare disease-free survival of suboptimally estrogen-suppressed patients treated with
           exemestane with that of patients with optimal suppression (exploratory analysis).

        -  Examine related endocrine function (FSH and LH) to further elucidate causes of
           suboptimal estrogen suppression.

      OUTLINE: This is a multicenter study.

      Blood samples are collected at baseline and at 3, 6, 12, 18, 24, 36, and 48 months for
      measurement of estrogen levels (estradiol [E2], estrone [E1], and estrone sulphate [E1S]) by
      gas chromatography-mass spectrometry and measurement of endocrine function (FSH and LH).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estrogen levels (estradiol [E2], estrone [E1], and estrone sulphate [E1S]) at different time points during the first 4 years of treatment with triptorelin in combination with either tamoxifen citrate or exemestane on clinical trial IBCSG-2402</measure>
    <time_frame>Four years after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who receive exemestane experiencing suboptimal estrogen suppression</measure>
    <time_frame>Four years after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of estrogen levels at different time points during treatment</measure>
    <time_frame>Four years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential predictive factors of ineffective estrogen suppression</measure>
    <time_frame>Four years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of optimal estrogen suppression during the first 6 and 12 months of treatment with regard to long-term estrogen suppression</measure>
    <time_frame>Four years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of disease-free survival of suboptimally estrogen-suppressed patients with that of patients with optimal suppression</measure>
    <time_frame>Four years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine function (FSH and LH)</measure>
    <time_frame>Four years after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Triptorelin plus tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triptorelin plus exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gas chromatography / tandem mass spectometry</intervention_name>
    <description>Determination of estrogen levels through gas chromatography.</description>
    <arm_group_label>Triptorelin plus tamoxifen</arm_group_label>
    <arm_group_label>Triptorelin plus exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed resected breast cancer

          -  Concurrent enrollment on clinical trial IBCSG-2402 (SOFT trial) required

               -  Randomized to receive triptorelin in combination with either tamoxifen citrate or
                  exemestane

          -  Hormone receptor status:

               -  Estrogen receptor- and/or progesterone receptor-positive tumor

        PATIENT CHARACTERISTICS:

          -  Premenopausal

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prudence Francis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salvatore Maugeri Foundation</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Oncologica, Policlinico Univeritario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INEN (Instituto de Enfermedades Neoplasicas)</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Md Anderson</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Dureta</name>
      <address>
        <city>Palma</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau i Santa Tecla</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital Gothenburg</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multidisciplinary Oncology Centre, CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Thun</name>
      <address>
        <city>Thun</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brust-Zentrum</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

